239
Participants
Start Date
October 27, 2022
Primary Completion Date
December 13, 2023
Study Completion Date
December 13, 2023
Cannabidiol oral solution
CBD 150 mg BID
Cannabidiol oral solution
CBD 300 mg BID
Placebo
Placebo BID
EPI-CBD-001-Site, New York
EPI-CBD-001-Site, Rochester
EPI-CBD-001 Site, Cedarhurst
EPI-CBD-001 Site, Jacksonville
EPI-CBD-001 Site, Maitland
EPI-CBD-001 Site, Orlando
EPI-CBD-001 Site, Lauderhill
EPI-CBD-001 Site, Chicago
EPI-CBD-001 Site, Oklahoma City
EPI-CBD-001 site, Wichita Falls
EPI-CBD-001 Site, Los Alamitos
EPI-CBD-001 Site, Encino
EPI-CBD-001 Site, Lemon Grove
EPI-CBD-001-Site, Oceanside
EPI-CBD-001 site, San Jose
EPI-CBD-001 Site, Portland
EPI-CBD-001 Site, Bellevue
Lead Sponsor
EmpowerPharm Inc.
INDUSTRY